Key facts
- US private equity firm TPG has acquired Optum UK for approximately $400 million.
- Optum UK's business includes EMIS, which provides electronic patient record systems to over half of GP practices in England.
- Critics, including doctors and MPs, are concerned about sensitive NHS patient data being controlled by a private equity firm.
- Concerns have been raised regarding TPG's international healthcare investments and alleged patient billing practices.
- TPG and EMIS assert that data security and patient privacy protections remain unchanged and are strictly governed by existing regulations.
A significant deal involving the transfer of control over sensitive NHS patient records to a US private equity firm has sparked widespread alarm. TPG, a prominent US investment firm, has acquired Optum UK, the healthcare technology business responsible for the electronic patient record system used by the majority of GP practices across England. The transaction, valued at approximately $400 million (£300 million), has drawn criticism from doctors, patient advocacy groups, and politicians who argue that such deals are being conducted with insufficient public scrutiny and inadequate safeguards for patient data.
Campaigners, such as the Doctors’ Association UK (DAUK), expressed deep concern that private equity now controls critical infrastructure for general practice, managing the records of millions of patients. They highlighted that the business model of private equity firms prioritizes investor returns over patient care, drawing parallels to previous controversies involving data handling by companies like Palantir. Calls have been made for the government to clarify existing data protection measures, outline protocols for future data handling if the asset is sold, and ensure parliamentary oversight for such transactions.
Helen Morgan, the Liberal Democrats’ health spokesperson, criticized the government for what she described as rubber-stamping deals without adequate protections, emphasizing the vulnerability of public services when sensitive NHS data is handed to foreign tech firms. She urged the government to support British technology companies instead.
Further concerns have been amplified by TPG’s international track record. An investigation by the International Consortium of Investigative Journalists (ICIJ) previously examined hospitals in Kenya owned by Evercare, a healthcare group backed by TPG’s Rise Fund. Allegations from this investigation included patients being burdened with excessive medical bills, with some reportedly required to provide land deeds as collateral. A spokesperson for TPG strongly refuted these allegations, asserting that the firm has invested significantly in improving quality and patient rights within Evercare and that any suggestion of prioritizing profits over patients is incorrect.
Anna Marriott, former health policy lead at Oxfam, echoed the sentiment that the deal should “ring major alarm bells,” emphasizing the lack of public scrutiny for a private equity firm with a controversial international healthcare record taking control of sensitive NHS data. She stressed the government's responsibility to guarantee the safety of patient records, noting that the increasing penetration of private equity into the health service is outpacing necessary regulatory frameworks.
EMIS, a key part of Optum UK, stated its longstanding commitment to the NHS and assured that data security and patient privacy have always been paramount, supported by rigorous controls and regulatory compliance. A spokesperson for EMIS also confirmed that the acquisition underwent and passed review by the UK government under the National Security and Investment Act 2021, asserting that patient data protections remain unchanged. TPG reiterated these assurances, stating that assertions of accessing, controlling, or utilizing NHS patient records are false and that the company is committed to reinforcing EMIS's existing high standards for data protection and patient privacy.